Use of Roche’s haemophilia A therapy Hemlibra expanded in the US
Roche’s Hemlibra has been approved in the US for routine prophylaxis of bleeding episodes patients with haemophilia A without factor VIII inhibitors.
According to Roche, Hemlibra is the only medicine that can be self-administered subcutaneously once weekly, every two weeks or every four weeks for haemophilia A with and without factor VIII inhibitors.
“Many preventative treatment options for people with haemophilia A without factor VIII inhibitors require intravenous infusions several times a week. Even then, people can still experience bleeds, and there has been a need for more treatment options,” said Michael Callaghan, MD, haematologist, Children’s Hospital of Michigan, Detroit.
http://www.pharmatimes.com/news/use_of_roches_haemophilia_a_therapy_hemlibra_expanded_in_the_us_1254634
According to Roche, Hemlibra is the only medicine that can be self-administered subcutaneously once weekly, every two weeks or every four weeks for haemophilia A with and without factor VIII inhibitors.
“Many preventative treatment options for people with haemophilia A without factor VIII inhibitors require intravenous infusions several times a week. Even then, people can still experience bleeds, and there has been a need for more treatment options,” said Michael Callaghan, MD, haematologist, Children’s Hospital of Michigan, Detroit.
http://www.pharmatimes.com/news/use_of_roches_haemophilia_a_therapy_hemlibra_expanded_in_the_us_1254634